BACKGROUND: The purpose of this study was to investigate the association between HPV 16 status and survival outcomes in patients with non-oropharyngeal squamous carcinoma (non-OPSCC). METHODS: Patients with non-OPSCC diagnosed between 2006 and 2016 were included in this study. The presence of HPV 16 DNA was confirmed by quantitative real-time polymerase chain reaction. Survival analysis was performed using Kaplan-Meier estimates, the Cox proportional hazards model, and propensity score matching (PSM). RESULTS: Overall, 1,539 patients with adequate specimens were identified, of whom 131 (8.51%) were positive for HPV 16. Compared to HPV 16-negative patients, the adjusted hazard ratios (aHR) for HPV 16-positive non-OPSCC patients were 0.77 and 0.81 for disease-specific survival (DSS) and overall survival (OS), respectively. Additionally, the larynx was the only subsite in which DSS was significantly improved. After PSM, cohorts consisted of 129 patients in the HPV 16-positive group and 129 in the HPV 16-negative group. HPV 16-positive non-OPSCC patients had favorable survival outcomes, however, these outcomes were not significantly different compared to HPV 16-negative patients. Stratified analysis performed according to primary site showed that only in the larynx was HPV 16-positive status a significant factor for predicting favorable DSS. CONCLUSIONS: Our findings indicate that HPV 16-positive non-OPSCC patients did not have significantly better survival outcomes compared to HPV 16-negative patients. 2019 Annals of Translational Medicine. All rights reserved.
BACKGROUND: The purpose of this study was to investigate the association between HPV 16 status and survival outcomes in patients with non-oropharyngeal squamous carcinoma (non-OPSCC). METHODS: Patients with non-OPSCC diagnosed between 2006 and 2016 were included in this study. The presence of HPV 16 DNA was confirmed by quantitative real-time polymerase chain reaction. Survival analysis was performed using Kaplan-Meier estimates, the Cox proportional hazards model, and propensity score matching (PSM). RESULTS: Overall, 1,539 patients with adequate specimens were identified, of whom 131 (8.51%) were positive for HPV 16. Compared to HPV 16-negative patients, the adjusted hazard ratios (aHR) for HPV 16-positive non-OPSCC patients were 0.77 and 0.81 for disease-specific survival (DSS) and overall survival (OS), respectively. Additionally, the larynx was the only subsite in which DSS was significantly improved. After PSM, cohorts consisted of 129 patients in the HPV 16-positive group and 129 in the HPV 16-negative group. HPV 16-positive non-OPSCC patients had favorable survival outcomes, however, these outcomes were not significantly different compared to HPV 16-negative patients. Stratified analysis performed according to primary site showed that only in the larynx was HPV 16-positive status a significant factor for predicting favorable DSS. CONCLUSIONS: Our findings indicate that HPV 16-positive non-OPSCC patients did not have significantly better survival outcomes compared to HPV 16-negative patients. 2019 Annals of Translational Medicine. All rights reserved.
Entities:
Keywords:
Human papillomavirus; head and neck cancers; non-oropharyngeal neoplasms; prognosis; squamous cell carcinoma
Authors: K Kian Ang; Jonathan Harris; Richard Wheeler; Randal Weber; David I Rosenthal; Phuc Felix Nguyen-Tân; William H Westra; Christine H Chung; Richard C Jordan; Charles Lu; Harold Kim; Rita Axelrod; C Craig Silverman; Kevin P Redmond; Maura L Gillison Journal: N Engl J Med Date: 2010-06-07 Impact factor: 91.245
Authors: Edwin P Martens; Wiebe R Pestman; Anthonius de Boer; Svetlana V Belitser; Olaf H Klungel Journal: Int J Epidemiol Date: 2008-05-03 Impact factor: 7.196
Authors: I Tinhofer; K Jöhrens; U Keilholz; A Kaufmann; A Lehmann; W Weichert; A Stenzinger; C Stromberger; K Klinghammer; E-T Becker; S Dommerich; K Stölzel; V M Hofmann; B Hildebrandt; L Moser; J Ervens; A Böttcher; A Albers; R Stabenow; A Reinecke; V Budach; B Hoffmeister; J D Raguse Journal: Eur J Cancer Date: 2015-01-23 Impact factor: 9.162
Authors: Hong Li; Sina J Torabi; Wendell G Yarbrough; Saral Mehra; Heather A Osborn; Benjamin Judson Journal: JAMA Otolaryngol Head Neck Surg Date: 2018-06-01 Impact factor: 6.223
Authors: Alex K Bryant; Elena J Sojourner; Lucas K Vitzthum; Kaveh Zakeri; Hanjie Shen; Cammie Nguyen; James D Murphy; Joseph A Califano; Ezra E W Cohen; Loren K Mell Journal: J Natl Cancer Inst Date: 2018-12-01 Impact factor: 13.506
Authors: Lindsey A Torre; Freddie Bray; Rebecca L Siegel; Jacques Ferlay; Joannie Lortet-Tieulent; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2015-02-04 Impact factor: 508.702
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702
Authors: Anish Sharma; Alice L Tang; Vinita Takiar; Trisha M Wise-Draper; Scott M Langevin Journal: Cancers (Basel) Date: 2021-07-22 Impact factor: 6.639